Lundbeck says FDA grants Fast Track status to narcolepsy drug candidate Lu AH69593

Reuters2026/07/23 07:01

By:Reuters

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

H. Lundbeck received FDA Fast Track designation for Lu AH69593, an oral orexin 2 receptor agonist for narcolepsy.
Lu AH69593 is in Phase 1b development, positioning the program for closer FDA interaction and a potentially faster review path.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. H. Lundbeck A/S published the original content used to generate this news brief via Cision (Ref. ID: 202607230300BITN____UKPR__EN_20260722-BIT-1039-0) on July 23, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Lundbeck says FDA grants Fast Track status to narcolepsy drug candidate Lu AH69593

You may also like

Crypto prices